Psychedelic Platform Field Trip Health Gets Uplisting Conditional Approval for Toronto Stock Exchange

Psychedelic Platform Field Trip Health Gets Uplisting Conditional Approval for Toronto Stock Exchange

Psychedelic healing platform Field Trip Health has received conditional approval to uplist to the Toronto Stock Exchange.
Psychedelic Drug Development Company Mynd Life Sciences Goes Public on the CSE

Psychedelic Drug Development Company Mynd Life Sciences Goes Public on the CSE

Psychedelic drug development company Mynd Life Sciences has gone public on the CSE.
Attorneys General, Organizations, Specialists Sue DEA for Access to Psilocybin for Terminally Ill Patients

Attorneys General, Organizations, Specialists Sue DEA for Access to Psilocybin for Terminally Ill Patients

,
A coalition of activists, organizations, and attorneys general are suing the DEA on behalf of terminally ill patients seeking psilocybin treatment.

MindMed Facing Competition From HAVN? Plus Financials and Phase 2 Trials (MNMD, CYBIN, HAVN, MYCO)

Hey guys! In this week’s industry specific news, we’ll cover some interesting developments for MindMed, Mydecine, Cybin, HAVN, and a private company called WAKE. One of the biggest highlights is that HAVN might enter in direct competition with MindMed by penetrating the cluster headaches market. Stay tuned till the end the hear more on this specific news! Timestamps: 0:00 - Intro 1:00 - MindMed Begins a Mescaline Study 4:35 - MindMed & The Chopra Foundation 8:30 - Cybin Progresses Phase 2a psilocybin study 11:56 - Mydecine announces Q1 Financials 14:16 - Havn Life Sciences enters the Cluster Headaches Game 16:30 - Wake Receives First-Ever Approval for Psilocybin for Anxiety & Depression Enjoy! Links: MindMed (MNMD/ MMED / MMQ)) Begins a Mescaline Study: https://mindmed.co/news/press-release/mindmed-announces-the-approval-of-mescaline-study/ MindMed Partners Up with The Chopra foundation: https://mindmed.co/news/press-release/the-chopra-foundation-and-mindmed-enter-into-letter-of-intent-to-partner-on-the-future-of-psychedelic-medicines-mental-wellbeing/ Cybin (CYBN) Progresses Phase IIa psilocybin film strip study: https://www.clinicaltrialsarena.com/news/cybin-phase-ii-psilocybin/ Mydecine (MYCO / MYCOF) Q1 Financials: https://psilocybinalpha.com/news/mydecine-reports-first-quarter-2021-financial-results-and-provides-business-update Havn Life Sciences (HAVN/ HAVLF/ 5NP) Begins to Study Cluster Headaches https://havnlife.com/havn-life-enters-into-agreement-to-acquire-clinical-stage-ip-for-development-of-lsd-derived-api-for-cluster-headaches/ Wake Receives First-Ever Approval for Psilocybin Microdose Study for Anxiety and Depression https://psychedelicspotlight.com/wake-psilocybin-microdose-study/ Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news! Follow us on social media! 🙌 Instagram: @thepsychedelicinvestor Email: thepsychedelicinvestor@gmail.com Facebook: @thepsychedelicinvestor Music: www.bensound.com Video editing: @themyaholy https://benzinga.grsm.io/jameshallifa... https://benzinga.grsm.io/thepsychedel... DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change. #MindMed #PsychedelicStocks #HAVN
Israelis and Palestinians Turn to Ayahuasca to Heal Conflict Wounds

Israelis and Palestinians Turn to Ayahuasca to Heal Conflict Wounds

New research has investigated the psychedelic ayahuasca in peace-building between conflict regions such as Israel and Palestine.

Interview With Dr. Gorman

In this episode of the Psychedelic Spotlight podcast, we speak with Dr. Ingmar Gorman who is the Co-Founder and Lead Trainer at Fluence, and a Principal Investigator for the Multidisciplinary Association for Psychedelic Studies ("MAPS").ya Health's Co-Founder and CEO, David Champion, discusses the importance of data and analytics in the growing psychedelic community.

Psychedelic Business Roundup- Mike Tyson’s New Investment

May 26, 2021-This week's Psychedelic Business News Round Up's top stories include: - Mike Tyson's Investment Into A Psychedelic-Focused Company - MDMA Moves Closer To Becoming An Approved Treatment For PTSD - A New Phase Psilocybin Microdosing…
Research Looks at Psychedelics for Autism Treatment

Research to Look at Psychedelics for Autism Treatment

New research from Nova Mentis will explore the potential benefits of psychedelics in treating autism spectrum disorders.
FDA Approves First-Ever MDMA Study for Therapist Volunteers to Better Treat PTSD Patients

FDA Approves First-Ever MDMA Study for Therapist Volunteers to Better Treat PTSD Patients

The FDA has approved a novel study allowing therapists who treat PTSD to take MDMA to better understand the treatment benefits.
What Is Changa?

What Is Changa? The Psychedelic You’ve Likely Never Heard Of (Yet)

What is changa? This DMT-containing psychedelic is gaining more recognition for its benefits, but you may still have not yet heard of it.